Share this post

Link to post

Share on other sites

Yeah I saw a clip on the news, they had to ask him if he was listening because he sat there like an annoyed 12 year old laughing, rolling his eyes, playing with a pen etc. Serious, serious mental problems. Serial killers are less obvious.

Link to post

Share on other sites

You won't be able to purchase Kanye West's newest album if Martin Shkreli has anything to say about it.

The pharmaceutical CEO, who recently made headlines after being accused of widespread securities fraud, took to Twitter on Thursday to offer the famed rapper $10 million in exchange for exclusive access to Kanye's newest album, "The Life of Pablo."

West, who is no stranger to controversy and social media himself, did not immediately reply.

Shkreli famously purchased the only copy of the Wu-Tang Clan's album "Once Upon a Time in Shaolin" for $2 million to "keep it from the people."

The purchase may eventually prove more costly for the former hedge fund manager, as a lawsuit surfaced on Tuesday claiming that the Wu-Tang Clan album contains illustrations ripped off from a New York artist.

The pharma bad boy's E-Trade stock account — valued at $45 million — lost a whopping $41 million in value since last month, when it was used to secure a $5 million criminal release bond.

Shkreli, 34, was convicted of some of the eight criminal counts that he had faced, which had included securities fraud and conspiracy to commit both securities fraud and wire fraud, after amore-than-month-long trialin Brooklyn, New York, federal court.

Of the eight counts, Shkreli was found guilty of three. Those included conspiracy to commit securities fraud, and two counts of securities fraud. He was found not guilty of five counts, including those related to wire fraud.

After getting their money, prosecutor said, Shkreli quickly lost much of it, and also used some of it to capitalize his infant pharmaceuticals company,Retrophin, even as he continued sending out financial statements to investors claiming positive returns.

Prosecutors said that he then looted the stock of Retrophin and cash from the young firm to pay off the hedge-fund investors who he had ripped off.

Shkreli was found not guilty of the counts that were tied to Retrophin, which were considered to be some of the most serious charges against him.

The charges were unrelated to Shkreli's first claim to public notoriety: raising the price of an anti-parasite drug called Daraprim by more than 5,000 percent in 2015, while heading another company, Turing Pharmaceuticals.

However, Shkreli was indicted in the federal case several months after that price increase came to light, and after he reveled in the widespread scorn that followed.